Effect of chemotherapy in metastatic prostate cancer according to race/ethnicity groups

No North‐American study tested the survival benefit of chemotherapy in de novo metastatic prostate cancer according to race/ethnicity. We addressed this void.

[1]  F. Saad,et al.  Effect of Chemotherapy on Overall Survival in Contemporary Metastatic Prostate Cancer Patients , 2021, Frontiers in Oncology.

[2]  F. Saad,et al.  Improvement in overall and cancer‐specific survival in contemporary, metastatic prostate cancer chemotherapy exposed patients , 2021, The Prostate.

[3]  F. Saad,et al.  Life expectancy in metastatic prostate cancer patients according to racial/ethnic groups , 2021, International journal of urology : official journal of the Japanese Urological Association.

[4]  F. Saad,et al.  Survival advantage of Asian metastatic prostate cancer patients treated with external beam radiotherapy over other races/ethnicities , 2021, World Journal of Urology.

[5]  J. Krell,et al.  Race reporting and diversity in US food and drug administration (FDA) registration trials for prostate cancer; 2006–2020 , 2021, Prostate Cancer and Prostatic Diseases.

[6]  F. Boccardo,et al.  Epidemiological Characteristics and Survival in Patients with De Novo Metastatic Prostate Cancer , 2020, Cancers.

[7]  A. Weiner,et al.  Survival following upfront chemotherapy for treatment-naïve metastatic prostate cancer: a real-world retrospective cohort study , 2020, Prostate cancer and prostatic diseases.

[8]  H. Klocker,et al.  Emerging promising biomarkers for treatment decision in metastatic castration-resistant prostate cancer. , 2020, Urologic oncology.

[9]  P. Kantoff,et al.  Survival of African-American and Caucasian men after sipuleucel-T immunotherapy: outcomes from the PROCEED registry , 2020, Prostate Cancer and Prostatic Diseases.

[10]  N. Lawrentschuk,et al.  Navigating systemic therapy for metastatic castration-naïve prostate cancer , 2020, World Journal of Urology.

[11]  Jonathan E. Shoag,et al.  PD30-10 DEFINITIVE AND SUSTAINED INCREASE IN PROSTATE CANCER METASTASES IN THE UNITED STATES , 2019, Urologic oncology.

[12]  I. Tannock,et al.  Overall Survival of Black and White Men With Metastatic Castration-Resistant Prostate Cancer Treated With Docetaxel. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  R. Cress,et al.  Changing Incidence of Metastatic Prostate Cancer by Race and Age, 1988-2015. , 2019, European urology focus.

[14]  T. Rebbeck.  Prostate Cancer Disparities by Race and Ethnicity: From Nucleotide to Neighborhood. , 2018, Cold Spring Harbor perspectives in medicine.

[15]  David F Jarrard,et al.  Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  J. Feinglass,et al.  The effect of socioeconomic status, race, and insurance type on newly diagnosed metastatic prostate cancer in the United States (2004-2013). , 2017, Urologic oncology.

[17]  M. Carducci,et al.  Impact of ethnicity on the outcome of men with metastatic, hormone‐sensitive prostate cancer , 2017, Cancer.

[18]  F. Saad,et al.  Improved cancer-specific free survival and overall free survival in contemporary metastatic prostate cancer patients: a population-based study , 2017, International Urology and Nephrology.

[19]  A. Ramos-Esquivel,et al.  Androgen-deprivation therapy plus chemotherapy in metastatic hormone-sensitive prostate cancer. A systematic review and meta-analysis of randomized clinical trials. , 2016, Urologic oncology.

[20]  S. Hitier,et al.  First-line treatment in senior adults with metastatic castration-resistant prostate cancer: A prospective international registry. , 2016, Urologic oncology.

[21]  R. Laing,et al.  Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial , 2016, The Lancet.

[22]  S. Culine,et al.  Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial. , 2014, The Lancet. Oncology.

[23]  R. deVere White,et al.  No improvement noted in overall or cause‐specific survival for men presenting with metastatic prostate cancer over a 20‐year period , 2014, Cancer.

[24]  Zhenyu Jia,et al.  Expression differences between African American and Caucasian prostate cancer tissue reveals that stroma is the site of aggressive changes , 2014, International journal of cancer.

[25]  Y. Homma,et al.  Oncological outcomes of the prostate cancer patients registered in 2004: Report from the Cancer Registration Committee of the JUA , 2011, International journal of urology : official journal of the Japanese Urological Association.

[26]  J. Xia,et al.  Efficacy of maximal androgen blockade versus castration alone in the treatment of advanced prostate cancer: a retrospective clinical experience from a Chinese medical centre. , 2010, Asian journal of andrology.

[27]  W. Sakr,et al.  Evidence supports a faster growth rate and/or earlier transformation to clinically significant prostate cancer in black than in white American men, and influences racial progression and mortality disparity. , 2010, The Journal of urology.

[28]  K. Armstrong,et al.  Racial Differences in Prostate Cancer Treatment Outcomes: A Systematic Review , 2005, Cancer nursing.

[29]  Kevin Regan,et al.  Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.